The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure

European Journal of Heart Failure

Volumn 7, Issue 4, 2005, Pages 461-467

  Reyes, Ariel J ^a  

^a Institute of Cardiovascular Theory Montevideo   (Uruguay)

Author keywords

Antioxidant capacity; Diuretics; Heart failure; Oxidative stress; Uric acid

Indexed keywords

ALLOPURINOL; AMILORIDE; BENDROFLUMETHIAZIDE; CAPTOPRIL; CHLORTALIDONE; CICLETANINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; OXIPURINOL; PERINDOPRIL; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TIENILIC ACID; TRIAMTERENE; URIC ACID;

ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; DIET RESTRICTION; DISEASE SEVERITY; FLUID RETENTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; KIDNEY FUNCTION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; SODIUM INTAKE; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

ALLOPURINOL; DIURETICS; FREE RADICAL SCAVENGERS; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY; OXIDATIVE STRESS; URIC ACID;

EID: 19544363918     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2004.03.020     Document Type: Article

References (116)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
2. B.M. Psaty, T.T. Lumley, and C.D. Furberg Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-analysis JAMA 289 2003 2534 2544
3. A.J. Reyes, and W.P. Leary The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: a connection with uric acid? Cardiovasc Drugs Ther 16 2002 485 487
4. A.J. Reyes, and W.P. Leary The increase in serum uric acid induced by diuretics could be beneficial to cardiovascular prognosis in hypertension: a hypothesis J Hypertens 21 2003 1775 1777
5. R. Harrison Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33 2002 774 797
6. A. Meneshian, and G.B. Bulkley The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction Microcirculation 9 2002 161 175
7. C.E. Berry, and J.M. Hare Xanthine oxidoreductase and cardiovascular disease-molecular mechanisms and pathophysiologic implications J Physiol 555 2004 589 606
8. L. Virag, E. Szabo, P. Gergely, and C. Szabo Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention Toxicol Lett 140-141 2003 113 124
9. D. Cooper, K.Y. Stokes, A. Tailor, and D.N. Granger Oxidative stress promotes blood cell endothelial cell interactions in the microcirculation Cardiovasc Toxicol 2 2002 165 180
10. D.A. Wink, K.M. Miranda, and M.G. Espey Mechanisms of the antioxidant effects of nitric oxide Antioxid Redox Signal 3 2001 203 213
11. T. Podzuweit, H. Beck, A. Muller, R. Bader, G. Gorlach, and H.H. Scheld Absence of xanthine oxidoreductase activity in human myocardium Cardiovasc Res 25 1991 820 830
12. F. Regoli, and G.W. Winston Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxyl radicals, and hydroxyl radicals Toxicol Appl Pharmacol 156 1999 96 105
13. R.J. Teng, Y.Z. Ye, D.A. Parks, and J.S. Beckman Urate produced during hypoxia protects heart proteins from peroxynitrite-mediated protein nitration Free Radic Biol Med 33 2002 1243 1249
14. A. Trostchansky, G. Ferrer-Sueta, and C. Batthyany Peroxynitrite flux-mediated LDL oxidation is inhibited by manganese porphyrins in the presence of uric acid Free Radic Biol Med 35 2003 1293 1300
15. S. Muraoka, and T. Miura Inhibition by uric acid of free radicals that damage biological molecules Pharmacol Toxicol 93 2003 284 289
16. G.L. Squadrito, R. Cueto, and A.E. Splenser Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid Arch Biochem Biophys 376 2000 333 337
17. S.R. Maxwell, H. Thomason, and D. Sandler Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus Eur J Clin Invest 27 1997 484 490
18. M. Habdous, B. Herbeth, and M. Vincent-Viry Serum total antioxidant status, erythrocyte superoxide dismutase and whole-blood glutathione peroxidase activities in the Stanislas cohort: influencing factors and reference intervals Clin Chem Lab Med 41 2003 209 215
19. S. Nojiri, H. Daida, and H. Mokuno Association of serum antioxidant capacity with coronary artery disease in middle-aged men Jpn Heart J 42 2001 677 690
20. W.S. Waring, D.J. Webb, and S.R. Maxwell Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers J Cardiovasc Pharmacol 38 2001 365 371
21. W.S. Waring, A.A. Convery, V. Mishra, A. Shenkin, D.J. Webb, and S.R. Maxwell Uric acid reduces exercise-induced oxidative stress in healthy adults Clin Sci (Lond) 105 2003 425 430
22. N.C. Ward, K.D. Croft, J.M. Hodgson, L.J. Beilin, and I.B. Puddey A case control comparison of total antioxidant capacity of plasma in treated and untreated hypertensive subjects J Hypertens 20 Suppl. 4 2002 S107 [Abstract]
23. T.N. Steele Importance and pathogenesis of diuretic-induced hyperuricemia J.B. Puschett A. Greenberg Diuretics IV: chemistry, pharmacology and clinical applications 1993 Elsevier Amsterdam 231 238
24. E.J. Weinman, G. Eknoyan, and N. Suki The influence of the extracellular fluid volume on the tubular reabsorption of uric acid J Clin Invest 55 1975 283 291
25. B.M. Egan, A.B. Weder, J. Petrin, and R.G. Hoffman Neurohumoral and metabolic effects of short-term dietary NaCl restriction in men. Relationship to salt-sensitivity status Am J Hypertens 4 1991 416 421
26. M.D. Fotherby, and J.F. Potter Metabolic and orthostatic blood pressure responses to a low-sodium diet in elderly hypertensives J Hum Hypertens 11 1997 361 366
27. A. de la Sierra, M.M. Lluch, and A. Coca Fluid, ionic and hormonal changes induced by high salt intake in salt-sensitive and salt-resistant hypertensive patients Clin Sci (Lond) 91 1996 155 161
28. M. Burnier, B. Weber, and H.R. Brunner The advantages of angiotensin II antagonism J Hypertens 12 Suppl. 2 1994 S7 S15
29. T. Yamamoto, Y. Moriwaki, S. Takahashi, Z. Tsutsumi, and T. Hada Effect of norepinephrine on the urinary excretion of purine bases and oxypurinol Metabolism 50 2001 1230 1233
30. A. Quinones Galvan, A. Natali, and S. Baldi Effect of insulin on uric acid excretion in humans Am J Physiol 268 1995 E1 E5
31. E.J. Johns Role of angiotensin II and the sympathetic system in the control of renal function J Hypertens 7 1989 695 701
32. E. Muscelli, A. Natali, and S. Bianchi Effect of insulin on renal sodium and uric acid handling in essential hypertension Am J Hypertens 9 1996 746 752
33. A. Tykarski Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion Nephron 59 1991 364 368
34. M.H. Alderman, H. Cohen, S. Madhavan, and S. Kivlighn Serum uric acid and cardiovascular events in successfully treated hypertensive patients Hypertension 34 1999 144 150
35. N.F. Chu, D.J. Wang, S.H. Liou, and S.M. Shieh Relationship between hyperuricemia and other cardiovascular disease risk factors among adult males in Taiwan Eur J Epidemiol 16 2000 13 17
36. P. Strazzullo, G. Barba, and F.P. Cappuccio Altered renal sodium handling in men with abdominal adiposity: a link to hypertension J Hypertens 19 2001 2157 2164
37. B.F. Culleton, M.G. Larson, W.B. Kannel, and D. Levy Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study Ann Intern Med 131 1999 7 13
38. L.V. Franse, M. Pahor, and M. Di Bari Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP) J Hypertens 18 2000 1149 1154
39. J. Fang, and M.H. Alderman Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey JAMA 283 2000 2404 2410
40. K. Sakata, T. Hashimoto, H. Ueshima, A. Okayama NIPPON DATA 80 Research Group Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged Eur J Epidemiol 17 2001 461 468
41. W.S. Waring, S.H. Adwani, O. Breukels, D.J. Webb, and S.R. Maxwell Hyperuricaemia does not impair cardiovascular function in healthy adults Heart 90 2004 155 159
42. F.P. Cappuccio, P. Strazzullo, E. Farinaro, and M. Trevisan Uric acid metabolism and tubular Na handling. Results of a population based study JAMA 270 1993 354 359
43. F.P. Cappuccio, P. Strazzullo, A. Siani, and M. Trevisan Increased proximal sodium reabsorption is associated with increased cardiovascular risk in men J Hypertens 14 1996 909 914
44. B. Kirschbaum Renal regulation of plasma total antioxidant capacity Med Hypotheses 56 2001 625 629
45. F. Leyva, S. Anker, and J.W. Swan Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure Eur Heart J 18 1997 858 865
46. F. Leyva, T.P. Chua, S.D. Anker, and A.J. Coats Uric acid in chronic heart failure: a measure of the anaerobic threshold Metabolism 47 1998 1156 1159
47. S. Osaki, T. Kinugawa, and A. Endo Impairment of urate excretion is an important mechanism for hyperuricemia in patients with heart failure J Card Fail 5 Suppl. 2 1999 60 [Abstract]
48. M. Orynchak, E.M. Neiko, and V.N. Seredyuk Insulin resistance and chronic heart failure J Hypertens 19 Suppl. 2 2001 S284 [Abstract]
49. L. Teodosiev Excretion of uric acid in cardiac decompensation Vutr Boles 18 1979 218 224 [Article in Bulgarian; the author read the abstract in English publicised by PubMed.]
50. S.N. Tereshchenko, N.N. Levchuk, V.N. Drozdov, and V.S. Moiseev Level of blood uric acid in patients with postinfarction heart failure Ter Arkh 72 2000 57 60 [Article in Russian; the author read the abstract in English publicised by PubMed.]
51. W. Doehner, M. Rauchhaus, and V.G. Florea Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance Am Heart J 141 2001 792 799
52. F. Leyva, S.D. Anker, and I.F. Godsland Uric acid in chronic heart failure: a marker of chronic inflammation Eur Heart J 19 1998 1814 1822
53. M.M. Hoeper, J.M. Hohlfeld, and H. Fabel Hyperuricaemia in patients with right or left heart failure Eur Respir J 13 1999 682 685
54. M. Cicoira, L. Zanolla, and A. Rossi Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy Am Heart J 143 2002 1107 1111
55. U. Landmesser, S. Spiekermann, and S. Dikalov Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase Circulation 106 2002 3073 3078
56. S.D. Anker, W. Doehner, and M. Rauchhaus Uric acid and survival in chronic heart failure: validation and application in metabolic, functional and hemodynamic staging Circulation 107 2003 1991 1997
57. P. Bettencourt, A. Ferreira, and P. Dias Predictors of prognosis in patients with stable mild to moderate heart failure J Card Fail 6 2000 306 313
58. M.C. Desco, M. Asensi, and R. Marquez Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol Diabetes 51 2002 1118 1124
59. P.C. Moorhouse, M. Grootveld, B. Halliwell, J.G. Quinlan, and J.M. Gutteridge Allopurinol and oxypurinol are hydroxyl radical scavengers FEBS Lett 213 1987 23 28
60. D.K. Das, R.M. Engelman, R. Clement, H. Otani, M.R. Prasad, and P.S. Rao Role of xanthine oxidase inhibitor as free radical scavenger: a novel mechanism of action of allopurinol and oxypurinol in myocardial salvage Biochem Biophys Res Commun 148 1987 314 319
61. B.M. Hoey, J. Butler, and B. Halliwell On the specificity of allopurinol and oxypurinol as inhibitors of xanthine oxidase. A pulse radiolysis determination of rate constants for reaction of allopurinol and oxypurinol with hydroxyl radicals Free Radic Res Commun 4 1988 259 263
62. S.D. Ricardo, J.F. Bertram, and G.B. Ryan Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol Exp Nephrol 3 1995 270 279
63. W.D. Johnson, K.L. Kayser, J.B. Brenowitz, and S.F. Saedi A randomized controlled trial of allopurinol in coronary bypass surgery Am Heart J 121 1991 20 24
64. M.A. Rashid, and G. William-Olsson Influence of allopurinol on cardiac complications in open heart operations Ann Thorac Surg 52 1991 127 130
65. T.P. Cappola, D.A. Kass, and G.S. Nelson Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy Circulation 104 2001 2407 2411
66. W. Guan, T. Osanai, and T. Kamada Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction J Cardiovasc Pharmacol 41 2003 699 705
67. W. Doehner, N. Schoene, and M. Rauchhaus Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies Circulation 105 2002 2619 2624
68. C.A. Farquharson, R. Butler, A. Hill, J.J. Belch, and A.D. Struthers Allopurinol improves endothelial dysfunction in chronic heart failure Circulation 106 2002 221 226
69. U. Landmesser, and H. Drexler Allopurinol and endothelial function in heart failure. Future or fantasy? Circulation 106 2002 173 175
70. N.A. Weimert, W.F. Tanke, and J.J. Sims Allopurinol as a cardioprotectant during coronary artery bypass graft surgery Ann Pharmacother 37 2003 1708 1711
71. P. Korantzopoulos, D. Galaris, D. Papaioannides, and K. Siogas The possible role of oxidative stress in heart failure and the potential of antioxidant intervention Med Sci Monit 9 2003 RA119 RA124
72. M. Ichinose, H. Sugiura, and S. Yamagata Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways Eur Respir J 22 2003 457 461
73. Z. Tsutsumi, Y. Moriwaki, S. Takahashi, T. Ka, and T. Yamamoto Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy Clin Chim Acta 339 2004 117 122
74. Y. Kinugasa, K. Ogino, and Y. Furuse Allopurinol improves cardiac dysfunction after ischemia-reperfusion via reduction of oxidative stress in isolated perfused rat hearts Circ J 67 2003 781 787
75. B.R. Lucchesi Free radicals and tissue injury Dialogues Cardiovasc Med 3 1998 3 22
76. S.T. Kau Diuretics: what we have and what we need Prog Pharmacol 6 3 1988 1 63
77. W.P. Leary, and A.J. Reyes Angiotensin I converting enzyme inhibitors and the renal excretion of urate Cardiovasc Drugs Ther 1 1987 29 38
78. C. Roberts, M. Homeida, and F. Roberts Effects of piretanide, bumetanide and furosemide on electrolyte and urate excretion in normal subjects Br J Clin Pharmacol 6 1978 129 133
79. A.J. Reyes Renal excretory profiles of loop diuretics-consequences for therapeutic application J Cardiovasc Pharmacol 22 Suppl. 3 1993 S11 S23
80. C.J. Roberts, A.J. Marshall, S. Heaton, and D.W. Barritt Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone Br Med J 1 1979 224 226
81. H. Krum, H. Nolly, and D. Workman Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients Hypertension 40 2002 117 123
82. J. Koskelainen, T. Turpeinen, H. Lehto, R. Lammintausta, S. Sarna, and J. Viikari Metabolic effects of hydrochlorothiazide and hydrochlorothiazide- amiloride and trichlormethiazide-triamterene combinations Curr Ther Res Clin Exp 37 1985 554 565
83. E.D. Frohlich Ticrynafen: a new thiazide-like but uricosuric antihypertensive diuretic N Engl J Med 301 1979 1378 1382
84. T. Tarrade, P. Berthet, J.L. Paillasseur, D. Bosquet, and M. Allard Efficacité antihypertensive et tolérance du cicletanine. Résultats obtenus en monothérapie sur une large population Arch Mal Coeur 82 Suppl. IV 1989 91 97
85. A.J. Reyes, W.P. Leary, and K. van der Byl Lack of effect of cicletanine on uric acid Am J Hypertens 13 2000 114A [Abstract]
86. J.E. Carlsen, L. Kober, C. Torp-Pedersen, and P. Johansen Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects Br Med J 300 1990 975 978
87. A.J. Reyes Diuretics in the therapy of hypertension J Hum Hypertens 16 Suppl. 1 2002 S78 S83
88. J.H. MacKay, K.E. Arcuri, A.I. Goldberg, S.M. Snapinn, and C.S. Sweet Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components Arch Intern Med 156 1996 278 285
89. M. Kochar, R. Guthrie, J. Triscari, K. Kassler-Taub, and R.A. Reeves Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension Am J Hypertens 12 1999 797 805
90. Y. Korduner, L. Käbin, and G. Hagbarth Low-dose chlorthalidone treatment in previously untreated hypertension Curr Ther Res Clin Exp 29 1981 208 215
91. G. Pollavini, D. Comi, and C. Grillo Multicentre randomized cross-over double-blind comparison between chlorthalidone and slow-release oxprenolol in mild-to-moderate hypertension Curr Ther Res Clin Exp 35 1984 467 475
92. J. Scholze for the East Germany Collaborative Trial Group A. Breitstadt, and V. Cairns Ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design J Hypertens 11 Suppl. 2 1993 S25 S33
93. B. Girvin, and G.D. Johnston A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients J Hypertens 16 1998 1049 1054
94. W. Haerer, U. Bauer, and N. Sultan Acute and chronic effects of diuretic monotherapy with piretanide in congestive heart failure-a placebo-controlled trial Cardiovasc Drugs Ther 4 1990 515 522
95. H. Nishijima, H. Yasuda, and K. Ito Acute and chronic hemodynamic effects of the basic therapeutic regimen for congestive heart failure. Diuretics, low salt diet and bed rest Jpn Heart J 25 1984 571 585
96. D.W. Dixon, C. Barwold-Gohlke, and R.M. Gunnar Comparative efficacy and safety of bumetanide and furosemide in long-term treatment of edema due to congestive heart failure J Clin Pharmacol 21 1981 680 687
97. R. Düsing, and L. Piesche Second line therapy of congestive heart failure with torasemide Prog Pharmacol Clin Pharmacol 8 1990 104 120
98. P.G.G. Gerlag, and J.M. van Meijel High-dose furosemide in the treatment of refractory congestive heart failure Arch Intern Med 149 1988 286 291
99. S. Paterna, P. Di Pasquale, and G. Parrinello Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure Eur J Heart Fail 2 2000 305 313
100. W.P. Leary, A.J. Reyes, K. van der Byl, and T.N. Acosta-Barrios Effects of captopril, hydrochlorothiazide and their combination on timed urinary excretion of water and electrolytes J Cardiovasc Pharmacol 7 Suppl. 1 1985 S56 S62
101. A.F. Lant, R.W. McNabb, and F.H. Noormohamed Kinetic and metabolic aspects of enalapril action J Hypertens 2 Suppl. 2 1984 37 42
102. M. Labeeuw, N. Pozet, P.Y. Zech, A. Hadj-Aïssa, J. Finaz de Villaine, and M. Laville Influence de l'administration aiguë de ramipril sur l'excrétion d'acide urique Arch Mal Coeur 80 1987 870 874
103. A.J. Reyes Uric acid in cardiovascular diseases and the uricosuric and hypouricaemic actions of angiotensin-converting enzyme inhibitors A.J. Reyes M.F.C. Maranhão Cardiovascular pharmacotherapy Proceedings of the 9th International Congress on Cardiovascular Pharmacotherapy 2000 Monduzzi Editore Bologna 235 240
104. A.J. Reyes, W.P. Leary, K. van der Byl, and J.P. Santoni Effects of the angiotensin-I converting enzyme inhibitor perindopril on timed urinary excretion of water and solutes in healthy subjects Curr Ther Res Clin Exp 44 1988 619 629
105. M.H. Weinberger Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension Br J Clin Pharmacol 14 Suppl. 2 1982 127S 131S
106. P.L. Malini, E. Strocchi, E. Ambrosioni, and B. Magnani Long-term antihypertensive metabolic and cellular effects of enalapril J Hypertens 2 Suppl. 2 1984 101 105
107. Leonetti G a nome del Gruppo Italiano di Studio di Zestoretic Confronto degli effetti metabolici ed emodinamici della monoterapia con idroclorotiazide e dell'associazione idroclorotiazide + lisinopril. (Uno studio multicentrico italiano) Minerva Cardioangiol 43 1995 389 398
108. R.D. Graham Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination J Hum Hypertens 5 Suppl. 2 1991 59 60
109. W. Hart Lisinopril-hydrochlorothiazide combination compared with the monocomponents in elderly hypertensive patients J Hum Hypertens 5 Suppl. 2 1991 85 89
110. D. Sorescu, and K.K. Griendling Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure Congest Heart Fail 8 2002 132 140
111. H. Takano, Y. Zou, H. Hasegawa, H. Akazawa, T. Nagai, and I. Komuro Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases Antioxid Redox Signal 5 2003 789 794
112. Y. Taniyama, and K.K. Griendling Reactive oxygen species in the vasculature: molecular and cellular mechanisms Hypertension 42 2003 1075 1081
113. K.C. Lin, H.Y. Lin, and P. Chou The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study J Rheumatol 27 2000 1501 1505
114. N. Nakanishi, K. Tatara, K. Nakamura, and K. Suzuki Risk factors for the incidence of hyperuricaemia: a 6-year longitudinal study of middle-aged Japanese men Int J Epidemiol 2 1999 888 893
115. M.R. Peixoto, E.T. Monego, and P.C. Jardim Diet and medication in the treatment of hyperuricemia in hypertensive patients Arq Bras Cardiol 76 2001 463 472
116. R.L. Prior, and G. Cao In vivo total antioxidant capacity: comparison of different analytical methods Free Radic Biol Med 27 1999 1173 1181